Related Experiment Videos
CRIPTO-1: a novel target for therapeutic intervention in human carcinoma
Nicola Normanno1, Antonella De Luca, Monica R Maiello
1Department of Experimental Oncology, INT-Fondazione Pascale, Via Mariano Semmola, I-80131 Naples, Italy. nicnorm@yahoo.com
International Journal of Oncology
|September 18, 2004
Summary
CRIPTO-1 (CR-1) is expressed in various human carcinomas and drives cancer cell growth. Inhibiting CR-1 with antisense oligonucleotides significantly reduced tumor growth in cell lines and mouse models, suggesting CR-1 as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- CRIPTO-1 (CR-1) is implicated in human carcinoma pathogenesis.
- Understanding CR-1 expression and function is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To investigate the expression of CR-1 mRNA and protein in human cancer cell lines.
- To evaluate the therapeutic potential of targeting CR-1 using antisense oligonucleotides.
Main Methods:
- Screening CR-1 expression using RT-PCR, real-time PCR, and immunocytochemistry.
- Assessing the effect of antisense oligonucleotides against CR-1, TGF-alpha, and AR on cancer cell growth.
- Evaluating the impact of antisense oligonucleotides on Akt activation and tumor xenograft growth in nude mice.
Main Results:
- CR-1 is expressed across multiple human carcinoma types.
- Anti-CR-1 antisense oligonucleotides significantly inhibited anchorage-independent growth of colon, ovarian, lung, and breast carcinoma cells.
- Treatment with CR-1 antisense oligonucleotides reduced CR-1 expression, Akt activation, and xenograft tumor growth.
Conclusions:
- CR-1 plays a significant role in the proliferation and survival of various carcinoma cells.
- CR-1 represents a promising novel therapeutic target for diverse carcinoma types.
- Antisense oligonucleotide-mediated inhibition of CR-1 demonstrates therapeutic efficacy in preclinical models.